Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors

A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer

(2021) Mengmeng Jiang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Combination of PD1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer

(2020) Ying Ma et al.   GASTROENTEROLOGY

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target

(2019) Juliane Medler et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity

(2019) Eric M. Tam et al.   Science Translational Medicine

Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer

(2018) Yingjie Nie et al.   Science Signaling

Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer

(2018) Yingjie Nie et al.   Science Signaling

Metal-isotope-tagged monoclonal antibodies for high-dimensional mass cytometry

(2018) Guojun Han et al.   Nature Protocols

Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary syndrome

(2018) H Torrey et al.   LEUKEMIA

Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs

(2017) Heather Torrey et al.   Science Signaling

Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer

(2017) Xin Chen et al.   Science Signaling

TNFR2: A Novel Target for Cancer Immunotherapy

(2017) Éva S. Vanamee et al.   TRENDS IN MOLECULAR MEDICINE

Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs

(2017) Heather Torrey et al.   Science Signaling

Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer

(2017) Xin Chen et al.   Science Signaling

Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells

(2016) M. Leclerc et al.   BLOOD

Soluble tumour necrosis factor receptor type II and survival in colorectal cancer

(2016) Ana Babic et al.   BRITISH JOURNAL OF CANCER

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

(2016) Thomas A Mace et al.   GUT

Pancreatic cancer

(2016) Terumi Kamisawa et al.   LANCET

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

(2016) Padmanee Sharma et al.   LANCET ONCOLOGY

Tumor necrosis factor receptor 2 promotes growth of colorectal cancer via the PI3K/AKT signaling pathway

(2016) Tao Zhao et al.   Oncology Letters

Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy

(2016) Geoffrey S. Williams et al.   Oncotarget

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Shedding of TNF receptor 2 by effector CD8+ T cells by ADAM17 is important for regulating TNF-α availability during influenza infection

(2015) Matthew P. DeBerge et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2

(2015) Alexander Ungewickell et al.   NATURE GENETICS

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma

(2014) Ahmad A Tarhini et al.   Journal of Translational Medicine

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Crosstalk of mTOR/S6K1 and Hedgehog Pathways

(2012) Yan Wang et al.   CANCER CELL

Circulating Levels of TNF Receptor II Are Prognostic for Patients with Peripheral T-cell Non-Hodgkin Lymphoma

(2012) C. Heemann et al.   CLINICAL CANCER RESEARCH

TNF signaling drives myeloid-derived suppressor cell accumulation

(2012) Xueqiang Zhao et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE